Last reviewed · How we verify
OLX10010
At a glance
| Generic name | OLX10010 |
|---|---|
| Also known as | a cell penetrating asymmetric small interference RNA (cp-asiRNA), targeting a gene involved in formation of fibrosis |
| Sponsor | Olix Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery (PHASE2)
- A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OLX10010 CI brief — competitive landscape report
- OLX10010 updates RSS · CI watch RSS
- Olix Pharmaceuticals, Inc. portfolio CI